Alignment Healthcare (NASDAQ:ALHC) COO Sells $274,040.24 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) COO Sebastian Burzacchi sold 15,361 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $274,040.24. Following the completion of the transaction, the chief operating officer directly owned 258,630 shares in the company, valued at $4,613,959.20. This trade represents a 5.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Alignment Healthcare Stock Down 0.2%

NASDAQ ALHC traded down $0.03 on Thursday, reaching $18.16. The stock had a trading volume of 3,987,587 shares, compared to its average volume of 3,191,394. The business’s 50-day moving average price is $20.57 and its 200 day moving average price is $18.78. Alignment Healthcare, Inc. has a 12-month low of $11.63 and a 12-month high of $23.87. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same quarter last year, the company posted ($0.16) earnings per share. The business’s revenue was up 44.4% on a year-over-year basis. Equities research analysts forecast that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Recent analyst upgrades/price-target raises provide near-term support (UBS raised target to $21, Piper Sandler to $30, JPMorgan to $26), and the consensus target remains above the current price—helping underpin valuation.
• Positive Sentiment: Solid quarterly results: February quarter beat EPS and revenue estimates (revenue +44% YoY; EPS beat by $0.10), showing growth momentum in Medicare Advantage enrollment and monetization that supports longer-term upside.
• Neutral Sentiment: Zacks ran a comparison piece weighing ALHC vs. BrightSpring (BTSG) for value investors — useful context but not a company-specific catalyst. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Reported short-interest data is effectively zero/NaN in the recent reports (likely a reporting quirk); it doesn’t indicate a build of short pressure currently.
• Negative Sentiment: Cluster of insider sales from senior executives — President Dawn Maroney sold 30,000 shares (~$524k at $17.48) and other officers (Andreas P. Wagner, Robert L. Scavo) sold sizable blocks (~11k–12k shares each). Heavy insider selling can signal liquidity needs or personal diversification and often weighs on sentiment. Maroney sale filing: Maroney Form 4
• Negative Sentiment: Additional insider filings: Andreas P. Wagner sales (Form 4) and Robert L. Scavo sale (Form 4) were also disclosed, adding to the headline of insider liquidation. Wagner filing: Wagner Form 4 · Scavo filing: Scavo Form 4
• Negative Sentiment: Independent sell-side views: Weiss Ratings reiterated a “sell (D-)” and Wall Street Zen trimmed its rating to a hold — these dissenting views add downside risk if they influence broader investor sentiment. Weiss Ratings · Wall Street Zen reference included in company coverage.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on ALHC shares. JPMorgan Chase & Co. increased their price objective on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Robert W. Baird set a $28.00 price objective on shares of Alignment Healthcare in a research note on Friday, January 30th. Piper Sandler lifted their target price on Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. KeyCorp reiterated an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.56.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ALHC. Summit Securities Group LLC acquired a new stake in shares of Alignment Healthcare in the 4th quarter worth approximately $26,000. Parallel Advisors LLC grew its holdings in shares of Alignment Healthcare by 87.7% in the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock worth $33,000 after acquiring an additional 773 shares during the last quarter. Larson Financial Group LLC acquired a new stake in Alignment Healthcare during the 3rd quarter worth about $33,000. First Horizon Corp acquired a new stake in Alignment Healthcare during the 4th quarter valued at $39,000. Finally, SBI Securities Co. Ltd. lifted its stake in Alignment Healthcare by 4,868.9% in the 2nd quarter. SBI Securities Co. Ltd. now owns 3,031 shares of the company’s stock worth $42,000 after acquiring an additional 2,970 shares in the last quarter. Institutional investors own 86.19% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.